<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19391">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02854449</url>
  </required_header>
  <id_info>
    <org_study_id>20161022</org_study_id>
    <nct_id>NCT02854449</nct_id>
  </id_info>
  <brief_title>Tumor Response in Hypofractionated Radiotherapy</brief_title>
  <acronym>TRHR</acronym>
  <official_title>Biomarkers of Tumor Response in Hypofractionated Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will follow-up different immune cell populations in the blood before, during and
      after high dose radiation therapy which should give new information of the efficacy of Local
      Hypofractionated Radiotherapy and a rationale for adjuvant immunotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Patient information and collection of a signed informed consent form

        -  Clinical data collection

        -  Blood samples of 5 mL:

             1. after registration, prior to the first fraction of radiotherapy

             2. during radiotherapy sessions

             3. one month, 3 months after the last radiotherapy session

        -  Storage of the blood samples at ambient temperature

        -  Transportation of the samples to the Institute of Biology of Lille (IBL) - CNRS UMR8161
           for analysis

        -  Destruction of the samples at the end of the analysis
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Number of immune cells</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Neoplasms</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receive local hypofractionated radiotherapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient requiring a hypofractionated irradiation;

          -  pathologically confirmed Unspecified Adult Solid Tumor

          -  Age ≥ 18 years old

          -  KPS≥70

          -  Signed written informed consent.

        Exclusion Criteria:

          -  Patient treated by chemotherapy, targeted or immunotherapy within 21 days before the
             first sampling,

          -  Pregnant or breastfeeding woman,

          -  Patient under guardianship or tutorship.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gao Xianshu, Master</last_name>
    <role>Study Chair</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bai Yun, Master</last_name>
    <email>flkmy1@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gao Xianshu, Master</last_name>
      <email>gao7777@139.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 1, 2016</lastchanged_date>
  <firstreceived_date>August 1, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Celia</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Immune Marker</keyword>
  <keyword>Immunologic Marker</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Dose Hypofractionation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
